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ABSTRACT
Background: Parkinson’s disease (PD) is a
neurodegenerative disease characterized by
motor manifestations, autonomic and
neurological disorders and sensorial
symptoms. Medication therapy management
(MTM) consists of a service undertaken by
pharmacists to optimize pharmacological
therapy results. This way, the pharmacist
monitors the treatment prescribed by the
doctor and formulates a healthcare plan to
guarantee the treatment’s effectiveness, safety
and convenience, thereby improving the
patient’s quality of life (QoL).
Objective: To analyze the effect of MTM upon
medicine-related problems, motor symptoms,
autonomic disorders and QoL of patients with
Parkinson’s disease, and describe the
pharmaceutical interventions.
Methods: Quasi-experimental uncontrolled
before-and-after study carried out between
September 2012 and March 2013 in a
community pharmacy. Pharmacotherapy data
were collected from medical prescriptions,
patient diaries, medical charts and all the
medicines (over-the-counter and prescription)
brought by the patients to the appointment
with the pharmacist. The medicine-related
problems were classified as indication,
effectiveness, safety and adherence.
Adherence was measured through clinical
interviews and the Morisky questionnaire. PD
symptoms were assessed according to the
patients’ and/or caregivers’ perceptions about
the On/Off state of the motor symptoms and
relief of the nonmotor symptoms. QoL was
assessed using the PDQ-39 scores. The
interventions were targeted to
patients/caregivers and/or doctors, with
pharmacological and non-pharmacological
measures.
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Results: Seventy patients were followed up,
showing a decrease in medicine-related
problems (1.67 ± 1.34 to 0.8 ± 0.9 (p\0.001),
positive impact on adherence (from 37 to 10
non-adherent patients, p\0.001), QoL
improvement related to emotional wellbeing
(p= 0.012) and autonomic disorder. Most
interventions were performed directly with the
patients (73.8%), including non-pharmacological
guidance (28.5%), pharmacological guidance
(24.3%) and rescheduling (13.6%).
Conclusions: To carry out MTM with PD
patients, the pharmacist’s expertise needs to
transcend the technical knowledge about the
PD pharmacological treatment. The study
showed a positive effect with a decrease in the
medicine-related problems after the
interventions, especially improving adherence
and patients’ QoL.
Keywords: Parkinson disease; Pharmaceutical
care; Medication therapy management
INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative
disease characterized by motor manifestation,
autonomic disorder, sensorial symptoms and
neurological disorder that compromises the
patient’s quality of life (QoL) [1, 2].
Due to the progressive nature of the disease,
the patient’s QoL is compromised in physical,
mental/emotional, social and economic aspects.
The most common and relevant factors
reviewed in the literature about the worsening
of PD patients’ QoL were bradykinesia, tremor,
rigidity, postural instability, gait disorder, pain,
fatigue, depression, and sexual and cognitive
disorders [3, 4]. A Brazilian study showed that
the major QoL determinants include mood
disorder (mainly depression), disability, PD
complications (dyskinesia and fluctuation) and
educational attainment [2].
Therapy for PD is effective in the treatment
of motor symptoms, but it does not prevent the
disease’s progression. The worsening of motor
symptoms associated with the occurrence of
non-motor symptoms evolves progressively.
This situation leads to dosage increase and
need of new medication. Some
antiparkinsonians, mainly levodopa, develop
motor complications (fluctuation and
dyskinesia) in the long term, making the
treatment complex, increasing the demands
for care and more expensive and invasive
procedures [5, 6].
As a result of the treatment, PD patients can
experience medicine-related problems, which
are also called DRPs—drug-related problems. ‘‘A
DRP exists when a patient experiences (or is
likely to experience) either a disease or
symptom having an actual or suspected
relationship with drug therapy’’ [7].
Medicine-related problems include issues
related to medicine effectiveness, adverse
reactions and non-adherence to the treatment.
Non-adherence to the treatment is one of the
most common medicine-related problems in
patients who suffer from chronic diseases. It has
been estimated that the PD patients’ adherence
to the treatment is only 39%, compromising the
benefits of the therapy [6]. Younger patients,
patients with complex therapeutic regimens
(several pills per day), high depression, and low
QoL are less adherent to the antiparkinsonian
treatment [8–10]. Clinical consequences of
non-adherence to the antiparkinsonian
treatment include loss of motor functions and
reduction in QoL [11, 12]. The commitment of
health professionals and patients together
contributes to improvement of treatment
adherence [5, 8, 13]. Furthermore,
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non-adherence increases PD-related costs
because of the increase in hospital admissions,
medical appointments and other healthcare
services [6].
Some studies have reported that the
participation of a pharmacist in a
multidisciplinary healthcare team promotes
clinical benefits for PD patients and is
considered a valuable healthcare strategy
[14, 15]. Medication therapy management
(MTM) is one of the pharmacist’s duties,
which consists of a service undertaken by the
pharmacist in conjunction with other health
professionals. MTM aims at optimizing the
pharmacological therapy results, so the
pharmacist monitors the results of the
treatment prescribed by the doctor and
elaborates a healthcare plan to guarantee the
treatment’s effectiveness, safety, and
convenience, and therefore improve the
patients’ QoL. MTM is based on a
patient-centered approach which considers the
patient as an active partner in the healthcare
process and takes into consideration the
patient’s clinical, family, social and economic
conditions [16–18].
In view of the benefits that MTM represents
for PD patients, and given the complexity of the
disease and treatment, this study aims to
analyze the effects of MTM on the patients’
QoL, motor and non-motor symptoms, and





before-and-after study [19] was carried out from
October 2012 to April 2013 in a community
pharmacy (a training unit) linked to the
pharmacy undergraduate course at the Federal
University of Santa Catarina and to the Municipal
Health Secretariat in Florianopolis, Brazil. This
community pharmacy dispenses the medicines
included in the Specialized Component of
Pharmaceutical Assistance (SCPA) of the
Brazilian Unified Health System (SUS). The SCPA
aims to guarantee the integrality of the
pharmacological treatment, especially for
chronic diseases whose medications have a high
cost or are of difficult access in the market. The
SCPA supplies the following antiparkinsonian
medicines: entacapone, tocapone, amantadine,
pramipexole, bromocriptine, cabergoline, and
selegiline. Such medicines are dispensed
according to the Clinical Protocol and
Therapeutic Guidelines for the PD treatment, as
defined by the Ministry of Health [20, 21].
Patients
At the moment of the study, 161 patients
diagnosed with Parkinson’s disease
(International Classification of Disease G20)
were registered in the SCPA pharmacy. The
patients and/or the caregiver were contacted
and invited to participate in this study during
the dispensing session of antiparkinsonian
medicines by pharmacist AAF during her shift.
After being informed about the MTM process,
the participating patients/caregivers signed an
Informed Consent Form (ICF) and the first
appointment was scheduled. Patients living in
nursing homes or patients with discontinued
treatment were excluded.
Medication Therapy Management Service
The MTM service was carried out by two
pharmacists qualified for clinical
pharmaceutical assessment who had
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knowledge about PD and its treatment.
Additionally, all the parameters included in
the assessment were agreed between pharmacist
and patient prior to the study in order to
standardize the data collection. The provision
of the MTM service considered the patient’s
health needs related to PD and co-morbidities.
The data record forms were designed based on
the Pharmacotherapy Workup and the Dader
methods [16, 22–24]. The form contained
information about demographics,
pharmacotherapy, lifestyle, co-morbidities,
memory, and cognition, PD symptoms, and QoL.
Pharmacotherapy data (indication, dose,
posology, scheduling, and reports on the
access to medicines) were collected from the
medical prescription, patient diary [25] and all
medicines (over-the-counter and prescription
medicines) brought by the patient to the
appointment with the pharmacist. Such data
were supplemented with information from the
medical chart. Adherence was measured
through clinical interviews (open questions
made during the interview in the first and
sixth appointments) and by the Morisky
questionnaire (self-reporting by answering
closed questions in the first, third, and sixth
appointments) [26].
Lifestyle data were collected in the clinical
interviews and from the patient’s diary.
Co-morbidity data were collected from
medical charts and test results brought by the
patient to the appointments. Memory and
cognition impairment data were collected with
the mini–mental state examination test [27]
which was applied in the second appointment.
The PD symptoms assessment was based on the
patients’ and/or caregivers’ perception about
the symptoms’ progression. The patients or
caregivers that reported bradykinesia, tremor
and/or rigidity during the period between their
doses were classified as off-state. The patients or
caregivers that did not report these symptoms
were classified as on-state. Non-motor
symptoms (e.g. autonomic disorder, insomnia,
hallucinations) were classified as relief or
non-relief. These data were collected
throughout the six appointments.
After analyzing the aforementioned data, the
pharmacist identified potential
medicine-related problems reported by the
patients in the appointments. The problems
were classified according to Cipolle et al. [16] as
indication, effectiveness, safety and adherence.
When a medicine-related problem was
identified, the pharmacist designed an
intervention procedure in order to solve it
based on clinical, familiar, and social context
data; the latter two were collected using the
genogram [28, 29] and ecomap [30–32] tools.
The interventions to resolve the detected
medicine-related or other health problems
referring to PD were targeted to
patients/caregivers and/or doctors. The
interventions targeting the patients/caregivers
included counseling, rescheduling, education
measures, changes in the pharmacotherapy
(only OTC medicines), and referral to other
healthcare services (e.g., phonoaudiology,
physiotherapy). The interventions were held
with the support of written instructions referring
to verbal counseling, educational material,
personalized calendar of the pharmacological
treatment and the pharmacotherapeutic diary
(meal and medication reminder). The
interventions targeting the doctors included
suggestions of changes in the therapeutic
regimen of prescription medicines (addition,
discontinuation, posology, or dosage form). The
doctors were informed about the
recommendations by means of letters based on
the best evidence available collected from
searches in the databases Pubmed, Cochrane,
Bireme, and Micromedex.
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In order to record the follow-up data, the
SOAP (Subjective, Objective, Assessment Plan)
[33] was used.
Main Outcomes Analyzed
The effects of MTM upon PD patients were
assessed considering QoL improvement or
maintenance as a primary outcome. QoL was
measured by means of the Parkinson’s Disease
Questionnaire (PDQ-39) in a legitimate
Brazilian Portuguese version. This is a
PD-specific questionnaire that consists of 39
questions distributed between eight multi-item
domains: mobility (ten questions), activities of
daily living (six questions), emotional wellbeing
(six questions), social support (three questions),
body discomfort (three questions), stigma (four
questions); cognition (four questions); and
communication (three questions) [34–36].
Primary outcomes include changes in the
general and specific PDQ-39 domain and
scores. Secondary outcomes include changes in
the On/Off state of motor symptoms and relief
of non-motor symptoms from the
patient’/caregiver’ perspective, as well as
solutions to medicine-related problems,
especially those related to adherence.
Data Analysis
The results of the descriptive analysis were
expressed as median ± standard deviation, and
frequency was expressed in percentage (%). For
the analysis, (1) the Student’s t test, (2) the
Fisher’s Chi square test (v2), and (3) the one-way
ANOVA test were used respectively for: (1)
calculating the association between 2 averages:
inter- and intra-groups; (2) calculating the
association between categorical variables; and
(3) comparing a categorical variable with the
average of another one. SPSS-Kappa Measure of
Agreement was used to analyze the
concordance between the Morisky Medication
Adherence Scale and the clinical interviews.
Confidence intervals of 95% and values of
p\0.05 were considered significant. The data
analysis was carried out using the software SPSS
Statistics 15.0 for Windows.
Ethical Issues
This research was approved by the Human
Ethics Committee at the Federal University of
Santa Catarina with Institutional Approval No.
1963/2011. All ethical aspects were in
accordance with the Declaration of Helsinki of
1964, as revised in 2013.
RESULTS
Seventy of the 161 PD patients registered in the
SCPA were included in the study. The main
reason why some patients declined to
participate was difficulty to get to the
pharmacy. Fifty-one of the 70 participating
patients completed the expected 6 months of
MTM. Figure 1 shows the sampling flowchart.
Fig. 1 Sampling ﬂowchart
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The socio-demographical baseline data of the
studied population is shown in Table 1.
In the first appointment, 35 patients
reported rigidity and 35 reported tremors as
predominant PD motor symptoms. The most
frequent autonomic disorders were constipation
(43%), speech disorder (36%), dysphagia (28%),
and urinary dysfunction (28%). The most
frequent neurological co-morbidities were
depression (42.3%), sleep disorder (30.8%),
and dementia associated with PD (28%).
Medicine-Related Problems
Types and frequency of the medicine-related
problems are shown in Table 2.
One hundred sixteen medicine-related
problems were identified (mean 1.7 ± 1.3 per
patient). Of the patients, 87.1% presented at
least one medicine-related problem in the first
appointment. Nine (7.8%) patients did not
present medicine-related problems over the
6 months of MTM.
The most frequent medicine-related problem
types were Adherence (non-adherence) (37.1%)
followed by Safety (31.0%), Ineffectiveness
(16.4%), and Indication (15.5%). Of the
Ineffectiveness type, 84.2% were related to
underdose, and in 88.9% of the Indication
type an additional medicine was needed.
Interventions
A total of 404 pharmaceutical interventions
were performed (mean 5.8 ± 3.1
interventions/patient). A number of 279
interventions (69.1%) were accepted and in
213 of them (76.3%) the health problem
(medicine-related or other health problems)
was resolved (Table 3). 103 (25.5%) of the 404
interventions were aimed to resolve the
medicine-related problems. These
interventions were more effective to resolve
the problems related to non-adherence (n = 43;
46.5%) and adverse reactions (n = 13; 68%). For
some of the identified problems, interventions
were not carried out by the pharmacist because
the patient had had a follow-up visit prior to the
appointment with the pharmacist and his/her
doctor had changed the treatment.
Furthermore, out of the 297 interventions
(73.5%) aimed to resolve PD-related problems,
200 (67.3%) were accepted and in 152 of these
(76%) the problem was resolved. The most
Table 1 Socio-demographical baseline data of PD patients
in the study (N = 70)
Sex Male: 64.3%
Female: 35.7%
Average age ± SD 69.4 ± 11




Type of medical assistance Public: 22.9%
Private: 62.9%
Mixeda: 14.2%
Self-declared skin color White: 85.7%
Black: 5.7%
Multiracial: 8.6%






More than 8 years: 55.7%
Assisted by a caregiver 37.1%
SD standard deviation
a Mixed = public ? private medical assistance
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Table 2 Classiﬁcation, type, and frequency of medicine-related problems
Classiﬁcation Type Frequency (%)
Indication Unnecessary medication 2 (1.7)
Necessity of additional medication 16 (13.8)
Effectiveness Ineffective medication 3 (2.6)
Underdosage 16 (13.8)
Safety Adverse reaction 19 (16.4)
High dosage 17 (14.6)
Adherence Non-adherence 43 (37.1)
Total 116 (100.0)
Based on Cipolle et al. [16]
Table 3 Pharmaceutical interventions performed, accepted, and solved by conduct (n = 404)
Conduct N (%) N accepted (%) N solved (%)
Non-pharmacological treatment guidance (nutrition, exercises, etc.) 115 (28.5) 74 (64.3) 53 (71.6)
Pharmacological treatment guidance (information about medication) 98 (24.4) 72 (73.5) 60 (83.3)
Rescheduling 55 (13.6) 49 (89.1) 33 (67.3)
Guidance on PD 49 (12.1) 36 (73.5) 30 (83.3)
Referral to specialistsa 17 (4.2) 8 (47.1) 4 (50.0)
Education for habit changing 13 (3.2) 10 (76.9) 7 (70.0)
Addition of a new medicationb 12 (3.0) 6 (50.0) 4 (66.7)
Guidance on the access to the medication 11 (2.7) 4 (36.4) 3 (75.0)
Medication discontinuationb 10 (2.5) 6 (60.0) 6 (100.0)
Guidance on another pathology 7 (1.7) 5 (71.4) 4 (80.0)
Change of medicationb 6 (1.5) 2 (33.3) 2 (100.0)
Guidance on the medication use 5 (1.2) 4 (80.0) 4 (100.0)
Change of dosageb 3 (0.7) 3 (100.0) 3 (100.0)
Change of dosage formb 3 (0.7) 0 (0.0) –
Total 404 279 213
a Physical therapists, speech therapists, physical education professionals. These health professionals were voluntary workers
at the Parkinson Association of Santa Catarina—APASC
b If the medicine was OTC, the pharmacist added a new medication. In the case of prescription medicines, the pharmacist
sent a letter to the doctor suggesting the changes
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frequent PD-related interventions included
guidance on the disease (24.6%),
pharmacological (23.5%), and
non-pharmacological (20.1%) treatments. Most
of the interventions (N = 92) were carried out in
order to resolve health problems related to
autonomic disorders, especially concerning
non-pharmacological measures, rescheduling,
and pharmaceutical indication.
The main interventions to resolve sleeping
problems included non-pharmacological and
rescheduling measures. Most of these
interventions were targeted to the patients
(87.5%); 71.4% of them were accepted and all
of them resolved the sleeping problems.
The number of interventions decreased over
time. 177 interventions (43.8%) were carried
out in the first appointment and 27 (15%) in the
sixth appointment. Among the factors
associated with the number of interventions
were age (inversely proportional variable), QoL
(significant positive association only in the
stigma domain; p = 0.055), and diagnosis time
(significant positive association p = 0.022) for
patients diagnosed with PD in a period of up to
2 years and between 5 and 10 years.
The MTM sessions showed that issues such as
self-knowledge, empowerment facing the disease
and treatment, stigma, participation in support
groups, caregiver/family strengthening,
encouragement to non-pharmacological
treatments and healthier life were not stimulated
byanyhealthprofessional involved inthepatient’s
care. However, the patients that were part of the
APASC support group (15.7% of the patients) were
already being helped with these issues.
MTM Outcomes
The outcomes before and after the MTM service
are described in Table 4. It consists of an
intention-to-treat (ITT) analysis.
Quality of Life
After the MTM service, all the PDQ-39 scores
improved; however, a statistically significant
improvement (p = 0.012) was perceived only in
the item related to emotional wellbeing (PDQ3).
In spite of the short period of analysis, these data
represent a positive clinical impact of MTM upon
the PD patients’ QoL. The improvement of the
PDQ-39 scores before and after MTM was not
correlated with adherence, cognition, age, or sex.
Motor and Non-Motor Symptoms
The On/Off state of motor symptoms from the
perspective of the patients/caregivers did not
vary from the first to the sixth appointments.
The results for the non-motor symptoms
showed that in general all the symptoms were
to some extent relieved after the MTM service.
Best results were obtained for the control of
constipation, dysphagia, gastric dysfunction,
and hypotension.
Medicine-Related Problems Resolution
After the interventions, the number of
medicine-related problems decreased
significantly (p\0.001) from 1.7 ± 1.3 in the
first appointment to 0.8 ± 0.9 in the sixth
appointment. The adherence evaluation in the
clinical interview verified a decline from 37 to
10 non-adherent patients (p\0.001). When
evaluated by the Morisky questionnaire,
adherence had a significant increase only
between the first and the third appointments,
from 28 to 34 adherent patients (p = 0.005). The
difference between the non-adherent patients
assessed in the first and the sixth appointments
was not statistically significant.
It was not possible to carry out a post-MTM
assessment with 12 of the patients (15.7%) as
they did not complete the 6 months of
follow-up, in addition to four other patients
who were not able to attend the appointment. It
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is worth noting that there were differences in the
results of the adherent patients at the end of the
MTM process (appointment 6) between the
Morisky and Clinical Interviews methods (kappa
value = 0.304; a 95%, p = 0.017); despite a
considerable concordance (but not high) found
between the methods in the first appointment
(kappa value = 0.333, a 95%; p = 0.007).
DISCUSSION
Parkinson’s disease is a complex condition due
to the progressive nature of its motor and
non-motor symptoms, in addition to the fact
that PD medicines quickly lose their
effectiveness and cause long-term side effects.
These characteristics create the necessity of a
comprehensive approach towards a constant
monitoring of the pharmacological therapy and
the PD effects on the patients’ QoL [37]. These
characteristics consider QoL as a primary
outcome in PD [3]. Furthermore, because of
the particularities of the disease, individualized
interventions are required.
As previously indicated, most of the
interventions were performed in a period of up
to 2 years and between 5 and 10 years after the
diagnosis, as these are the two critical periods in
Table 4 Outcomes reached after 6 months of MTM (N = 70)
Outcome Initial value After 6 months p
QoL PDQ 39 Reduction in all domains NS
PDQ39_3 (emotional
wellbeing) (mean ± SD)
39.12 ± 26.54 36.89 ± 27.56 0.012
Motor symptomsa On 60% 58.6% NS
Off 40% 22.9%
Not assessedb 0 18.6%
Non-motor symptoms (patients) Constipation 27 9 \0.001
Dysphagia 8 3 0.001
Gastric dysfunction 7 0 0.008
Speech disorder 14 11 \0.001
Hypotension 6 0 0.014
Urinary incontinence 2 1 0.029
Sleep disorder 6 3 \0.001
Anxiety 3 1 0.043
DRP Problem resolved (mean ± SD) 1.7 ± 1.3 0.8 ± 0.9 \0.001
Adherence Clinical interview 37 non-adherent 10 non-adherent 0.001
Morisky–Green–Levine 42 non-adherent 20 non-adherent NS
NS non-signiﬁcant, PDQ-39_3 third domain of PDQ-39, SD standard deviation, DRP drug-related problem
a The patient’s perception about the On/Off state after taking the medicines
b Not assessed: when neither the patient or the caregiver was able to attend the appointment and someone else went to the
pharmacy to get the medicines for them
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the PD patient’s life. Up to 2 years, the patient
experiences a period of adaptation and
acceptance of the diagnosis. In the period
from 5 to 10 years, the PD patient faces
complications related to the treatment and the
disease’s progression [38].
Based on MTM, the analysis detected health
problems related and not related to medicines. Our
results demonstrate that even though most of the
identified health problems were not
medicine-related, they could be resolved by
pharmaceutical interventions. For instance,
autonomic disorders were one of the most
frequent problems not related to medicines and
can result from the disease’s progression and/or
antiparkinsonian medication side effects. Their
negative effects on the PD patients’ QoL were also
mentionedinother studies [39–41].Thesymptoms
can be relieved by means of nonpharmacological
measures or by OTC medicines. Therefore, this
type of interventions became important in the
pharmaceutical practice.
Although there are few studies about
medicine-related problems in PD patients, the
results of the present study were similar to those
of other published papers. Our results show that
the medicine-related problems were more
frequently related to non-adherence, adverse
reactions, necessity of additional medication
and underdose. In another study carried out in
community pharmacies, most DRPs
concentrated on the need of additional
medicines (26.3%) and adverse reactions
(12.4%) [14]. In another study at a nursing
home, most DRPs concentrated on unnecessary
medications (28%) and underdose (14%) [15].
According to Schro¨der et al. [14], underdose
may be associated with the prevention of
adverse reactions to dopaminergic
medications. Moreover, the medicine-related
problems associated with the necessity of
additional medication may stem from the fact
that the clinical practice focuses on motor
rather than non-motor symptoms, which
remain underestimated and untreated.
Similarly to other studies, our results show
that non-adherence is the main medicine-related
problem. This finding highlights the importance
of health professionals following up the patient’s
medication use in order to investigate if the
symptoms are a consequence of non-adherence
or of the disease’s progression. In this way,
unnecessary dosage change or addition of new
medicines can be avoided, reducing the risk of
adverse events [8, 14, 42, 43].
One of the key factors to improve adherence
is the patients’/caregivers’ knowledge about the
disease and awareness of the consequences of
discontinuing the medicine. This is the reason
why it is crucial to consider the patient as an
active partner in the healthcare process. Good
communication between the health
professional and the patient is fundamental
for effective clinical practice and for adherence
improvement. Some causes of non-adherence
include the patient’s search for other treatment
options, especially for the cure (mysticism,
beliefs), and discontinuation of the treatment
in case-positive effects are not experienced.
Moreover, our results corroborate those
reported by Navarro-Peternella and Marcon
[44] ,which demonstrated the necessity of
individualized professional interventions based
on actions that represent the real needs of the
PD patient and/or caregiver. Guidance and
information about the disease, its progression,
and ways of facing it are fundamental for
patient, caregiver, and family. The healthcare
services for PD patients must aim to minimize
the limitations resulting from the disease’s
progression and contribute to the
improvement or maintenance of their QoL [3].
Regarding the outcomes of the MTM service
related to QoL, and despite the short period of
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analysis, this study produced a positive clinical
impact. It is worth remarking that one of the
health professional’s biggest challenges is to
prepare his/her therapeutic plan in a way that
the patient’s QoL reaches a level that can be
considered good [44, 45].
The improvement of the PDQ-39 score
regarding emotional wellbeing after the MTM
process confirms the previously reported
humanistic positive impacts of MTM on the
patient’s life [18, 46]. During this process, the
patient is seen as an individual with rights,
knowledge, and experience and is treated as a
partner in the planning of his/her care, being
responsible for taking the final decision in the
therapeutic conduct [16]. This horizontal
relationship between pharmacist and patient
generates a transparent environment of trust
and credibility necessary for establishing a
therapeutic alliance. In addition the
perception of the patient as the central
figure of the pharmaceutical care within their
family and social context, singularity,
complexity, and subjectivity contributed to a
more comprehensive care. This way of
generating healthcare may have contributed to
the improvement of the PD patient’s wellbeing.
MTM was not able to improve or stabilize the
patients’ motor symptoms. A contributing
factor is the absence of medicines that actually
delay the disease’s progression, which
undoubtedly leads to the worsening of the
motor symptoms. Nevertheless, MTM has a
considerable impact on the relief of
non-motor symptoms, thus contributing to
the PD patients’ QoL.
Variations in the results of adherence
assessed by different methods were also
reported by Perseguer-Torregrosa et al. [47].
This difference reflects the way that each
method considers the patient’s role during the
therapy. While the Morisky questionnaire
evaluates adherence as the simple act of taking
the medication (compliance), the clinical
interview method sees the patient as an active
partner in the adherence process and considers
the patient’s will to collaborate with the
treatment (concordance) [48, 49]. In this
sense, once the most practical method to
evaluate the treatment adherence, especially
for elderly patients, is by interviewing the
patients or their caregivers [50], the adherence
improvement assessed in our study can be
considered a significant result of the MTM
service for PD patients.
Limitations
This study was conducted at a public
community pharmacy which is the only
outpatient setting that dispenses
antiparkinsonian medicines in the city, except
levodopa which is dispensed at primary
healthcare pharmacies. As we used the
convenience sampling method including only
the patients that we could contact instead of a
random sample, a selection bias may have
occurred. However, the characteristics of the
population under analysis are similar to those
reported in other studies [51–55].
The sample loss can be considered a limiting
factor of the statistical analysis. Nevertheless,
the results can be considered relevant from a
clinical point of view, once there was a decrease
from 42 to 20 in the number of non-adherent
patients. Since 15 patients did not complete the
MTM process, the number of interventions per
patient over the 6 months may have been
underestimated.
Another limitation of the study was the
unavailability of a neurologist. In an MTM
service, this partnership is very important to
achieve the desired outcomes, since many
interventions need the doctor’s collaboration.
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The quantitative data on humanistic aspects
were out of the scope of the study. Therefore,
further studies are needed for statistical
analyses. For the reason that some
interventions to improve adherence were
related to changes in the medication regimen,
it was not possible to analyze whether the
outcomes were driven by medication changes
or compliance.
CONCLUSION
In order to carry out an MTM service with PD
patients, the pharmacist’s expertise needs to
transcend their knowledge about the
pharmacological treatment.
Non-pharmacological measures are
fundamental to relieve non-motor symptoms
(autonomic and neurological disorders), which
are not assessed by the PDQ-39 but have an
important impact on the PD patients’ QoL. The
changes in the individual, family, and social
dynamics caused by the disease must be also
understood by the pharmacist so that he/she
can perform a service based on a comprehensive
care perspective.
The interventions resulting from the MTM
service contributed to improve or to maintain
the PD patients’ QoL, especially their emotional
wellbeing. MTM had a positive effect in the
decrease of medicine-related problems,
especially regarding improvements in the
treatment adherence. These results represent
clinical and humanistic outcomes of the MTM
service.
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